COCP Cocrystal Pharma, Inc.
Price Chart
Executive Summary
Cocrystal Pharma announced the discovery of novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza, with in vitro potency data showing IC50 <50 nM against hantaan virus. The press release highlights the potential to address significant unmet medical needs, but no financial data, guidance, or clinical trial results were provided.
Actionable Insight
The announcement expands Cocrystal's pipeline into high-unmet-need viral indications with no approved treatments, which could attract partnership interest. However, the data is early-stage in vitro only — monitor for in vivo animal data and any collaboration announcements. The $16M market cap makes this a high-risk binary event stock; position sizing should reflect that.
Key Facts
- Novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza announced
- In vitro potency data shows IC50 <50 nM against hantaan virus
- Andes hantavirus outbreak on cruise ship infected up to 11, resulting in 3 deaths
- No approved treatments or vaccines for hantavirus or bunyavirus
- CDI-988, a first pan-viral protease inhibitor, advanced to Phase 1b norovirus challenge study in the US
- No financial data, guidance, or clinical trial results were provided in the filing
Financial Impact
No financial figures provided; pre-revenue clinical-stage biotech with $16M market cap
Risk Factors
- Early-stage preclinical data may not translate to clinical efficacy
- No revenue or near-term catalysts to support valuation
- Dilution risk given $16M market cap and cash burn from multiple programs
- Competition from other antiviral developers targeting similar viruses
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025172 |
| Exhibit: ex99-1.htm | 0001493152-26-025172 |
| Document: 0001493152-26-025172-index-headers.html | 0001493152-26-025172 |
| Document: 0001493152-26-025172-index.html | 0001493152-26-025172 |
| Document: 0001493152-26-025172.txt | 0001493152-26-025172 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
8-K
| — | awaiting T+1 | — | — |
|
Jun 3, 2026
6d ago
|
8-K
| $1.06 $1.05 | ▼ −0.94% | ▼ −1.34% | $1.02 (−3.77%) |
|
May 27, 2026
13d ago
|
DEFA14A
| $1.13 $1.12 | ▼ −0.89% | ▼ −1.12% | $1.02 (−9.73%) |
|
May 26, 2026
14d ago
|
8-K
| $1.13 $1.12 | ▼ −0.89% | ▼ −0.90% | $1.02 (−9.73%) |
|
May 15, 2026
25d ago
|
Press Release
| $1.20 $1.18 | ▼ −1.67% | ▼ −1.60% | $1.02 (−15.00%) |
|
May 4, 2026
5w ago
|
EFFECT
| $1.31 $1.38 | ▼ −5.34% | ▼ −4.55% | $1.02 (+22.14%) |
|
Apr 2, 2026
9w ago
|
8-K
| $1.51 $1.50 | ▼ −0.66% | ▼ −1.14% | $1.02 (−32.45%) |
|
Mar 31, 2026
10w ago
|
8-K
| $1.01 $1.02 | ▲ +0.99% | ▲ +0.24% | $1.02 (+0.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access